<div id="readability-page-1">03:41 PM EST, 12/23/2025 (MT Newswires) -- Health care stocks were mixed late Tuesday afternoon, with the NYSE Health Care Index fractionally higher and the State Street Health Care Select Sector SPDR ETF (XLV) easing 0.3%.The iShares Biotechnology ETF (IBB) shed 0.4%.In corporate news, Pfizer ( PFE ) shares were down 1.4% after it said Tuesday that a participant in its long-term extension trial evaluating Hympavzi in hemophilia died after serious adverse events of cerebellar infarction and cerebral hemorrhage.Novo Nordisk ( NVO ) shares jumped past 7% after it said late Monday the US Food and Drug Administration approved its Wegovy pill for weight management and to reduce the risk of major adverse cardiovascular events.Johnson &amp; Johnson ( JNJ ) has been ordered by a Baltimore jury to pay more than $1.5 billion to a single plaintiff, who claimed that the use of the pharmaceutical giant's talc-based baby powder products caused her cancer. Johnson &amp; Johnson ( JNJ ) shares were shedding 1%.RxSight ( RXST ) shares fell past 10% after the company said late Monday that chief financial officer Shelley Thunen will transition from her role. Thunen will remain with the company until the sooner of the appointment of a new CFO or Jan. 31, 2026. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

Health care stocks showed mixed performance, with NYSE Health Care Index slightly up and XLV down 0.3%. Pfizer shares fell 1.4% due to a trial participant's death. Novo Nordisk shares rose over 7% after FDA approved its Wegovy pill. Johnson & Johnson was ordered to pay $1.5 billion in a talc-related lawsuit, causing shares to drop 1%. RxSight shares fell over 10% following CFO transition announcement.

- Health care stocks showed mixed performance, with the NYSE Health Care Index slightly up while the State Street Health Care Select Sector SPDR ETF declined by 0.3%.  
- Pfizer's shares fell 1.4% following a reported death in its trial for Hympavzi, while Novo Nordisk saw a 7% rise after FDA approval for its Wegovy pill.  
- Johnson & Johnson was ordered to pay over $1.5 billion to a plaintiff due to talc-related cancer claims, leading to a 1% drop in their shares, and RxSight's stock decreased by over 10% amid CFO transition news.

Sector Update: Health Care Stocks Mixed Late Afternoon